Triflusal is primarily used as an antiplatelet agent in the prevention of thrombotic events, particularly in patients who have suffered strokes or transient ischemic attacks. It works by inhibiting platelet aggregation, reducing the risk of blood clot formation in arteries. Unlike aspirin, triflusal has a more selective action on platelets with a lower incidence of gastrointestinal side effects, making it a favorable alternative in long-term antiplatelet therapy. It is also reported to have anti-inflammatory and antioxidant properties, which may contribute to its neuroprotective effects in cerebrovascular diseases. Triflusal is commonly prescribed in certain countries as part of secondary prevention strategies in cardiovascular and cerebrovascular conditions.